Company profile
Kymera Therapeutics, Inc.
NASDAQ: KYMR · Healthcare · Biotechnology
#470 of 1,418 Healthcare companies by revenue29th-percentile growth
EA Score
54DFH 57DQ 55GM 36SS 66
v0.1 · 65/100 weight · provisional
↑ Altman-Z, market scale · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$105.0M
Rev growth YoY (TTM)
+134.8%
Net income (FY)
-$311.4M
Employees
238
as of 2026-08-06
Market cap
$8.7B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$39.2M$39.2M2025
Net income-$311.4M-$311.4M2025
Operating income-$349.4M-$349.4M2025
Total assets$1.7B$1.7B2025
Liabilities$163.1M$163.1M2025
Equity$1.6B$1.6B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Kymera Therapeutics, Inc.’s revenue?
Kymera Therapeutics, Inc. booked $39.2M in FY2025 revenue, contracting 17% year over year — slower than 71% of Healthcare companies we track, at a -794.0% net margin.
Peers · Healthcare
Valeo Pharma Inc.——Enveric Biosciences, Inc.31DBig Tree Group, Inc.——Interpace Biosciences, Inc.74BPalvella Therapeutics, Inc.54DUtah Medical Products, Inc.80B+Neighbors
Middlesex →Key facts
CEONello Mainolfi
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, MA
ExchangeNASDAQ: KYMR
Employees238
IPO date2020-08-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.